Cargando…
Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
Immune-Mediated Necrotizing Myopathy (IMNM) after vaccination has been reported previously, however it is rare after COVID-19 vaccination. We report the first case of IMNM two weeks after vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine. There was a probable temporal relationship between...
Autores principales: | Ansari, B., Najafi, M.A., Kheradmand, M., Najafi, F., Najafi, M.R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889262/ https://www.ncbi.nlm.nih.gov/pubmed/36754672 http://dx.doi.org/10.1016/j.neurol.2022.11.009 |
Ejemplares similares
-
Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023) -
Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries
por: Sharun, Khan, et al.
Publicado: (2021) -
Utility of skin testing in assessment of post-AZD1222 vaccine (AstraZeneca) allergic reactions: case series in Vietnam
por: Vu, Mai Thi, et al.
Publicado: (2021) -
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
por: Fragoso, Yara D, et al.
Publicado: (2022) -
Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory
por: Yoon, Jong Pil, et al.
Publicado: (2022)